$75.01
Gilead Sciences, Inc. is a biopharmaceutical company that develops innovative treatments for life-threatening diseases.
Revenue is up for the last 2 quarters, 13.6M → 6.59B (in $), with an average increase of 99.8% per quarter
Netprofit is up for the last 2 quarters, -7.4M → 2.13B (in $), with an average increase of 100.4% per quarter
In the last 1 year, Eli Lilly And Company has given 76.8% return, outperforming this stock by 57.5%
In the last 3 years, Eli Lilly And Company has given 266.4% return, outperforming this stock by 245.9%
0.87%
Downside
Day's Volatility :1.63%
Upside
0.77%
22.58%
Downside
52 Weeks Volatility :31.75%
Upside
11.85%
Period | Gilead Sciences Inc. | Sector (Health Care) | Index (NASDAQ Composite) |
---|---|---|---|
3 Months | -2.02% | -1.4% | -2.1% |
6 Months | -5.74% | 2.2% | 11.7% |
1 Year | 20.32% | 6.0% | 21.6% |
3 Years | 20.5% | 26.3% | 21.1% |
Market Capitalization | 93.5B |
Book Value | $16.97 |
Dividend Share | 2.96 |
Dividend Yield | 3.99% |
Earnings Per Share (EPS) | 4.35 |
PE Ratio | 17.24 |
PEG Ratio | 0.72 |
Wall Street Target Price | 91.04 |
Profit Margin | 20.03% |
Operating Margin TTM | 35.75% |
Return On Assets TTM | 9.77% |
Return On Equity TTM | 26.35% |
Revenue TTM | 27.4B |
Revenue Per Share TTM | 21.87 |
Quarterly Revenue Growth YOY | 5.4% |
Gross Profit TTM | 21.6B |
EBITDA | 12.2B |
Diluted Eps TTM | 4.35 |
Quarterly Earnings Growth YOY | -0.09 |
EPS Estimate Current Year | 6.61 |
EPS Estimate Next Year | 7.25 |
EPS Estimate Current Quarter | 1.64 |
EPS Estimate Next Quarter | 1.88 |
What analysts predicted
Upside of 21.37%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 26.1B | ↓ 14.09% |
Net Income | 4.6B | ↓ 65.72% |
Net Profit Margin | 17.73% | ↓ 26.7% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 22.1B | ↓ 15.24% |
Net Income | 5.5B | ↑ 17.87% |
Net Profit Margin | 24.65% | ↑ 6.92% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 22.4B | ↑ 1.46% |
Net Income | 5.4B | ↓ 1.26% |
Net Profit Margin | 23.99% | ↓ 0.66% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 24.7B | ↑ 9.98% |
Net Income | 123.0M | ↓ 97.72% |
Net Profit Margin | 0.5% | ↓ 23.49% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 27.3B | ↑ 10.6% |
Net Income | 6.2B | ↑ 4960.98% |
Net Profit Margin | 22.8% | ↑ 22.3% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 27.3B | ↓ 0.09% |
Net Income | 4.6B | ↓ 26.23% |
Net Profit Margin | 16.83% | ↓ 5.97% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 6.6B | ↓ 9.03% |
Net Income | 19.0M | ↓ 95.03% |
Net Profit Margin | 0.29% | ↓ 4.98% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 6.3B | ↓ 5.01% |
Net Income | 1.1B | ↑ 5921.05% |
Net Profit Margin | 18.27% | ↑ 17.98% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 7.0B | ↑ 12.49% |
Net Income | 1.8B | ↑ 56.38% |
Net Profit Margin | 25.4% | ↑ 7.13% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 7.4B | ↑ 4.93% |
Net Income | 1.6B | ↓ 8.33% |
Net Profit Margin | 22.2% | ↓ 3.2% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.6M | ↓ 99.82% |
Net Income | -7.4M | ↓ 100.45% |
Net Profit Margin | -54.41% | ↓ 76.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.6B | ↑ 48422.06% |
Net Income | 2.1B | ↓ 28978.38% |
Net Profit Margin | 32.38% | ↑ 86.79% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 70.3B | ↑ 23.35% |
Total Liabilities | 49.8B | ↑ 32.35% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 63.7B | ↓ 9.4% |
Total Liabilities | 42.1B | ↓ 15.35% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 61.6B | ↓ 3.22% |
Total Liabilities | 39.0B | ↓ 7.51% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 68.4B | ↑ 11.0% |
Total Liabilities | 50.2B | ↑ 28.76% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 68.0B | ↓ 0.67% |
Total Liabilities | 46.9B | ↓ 6.57% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 63.1B | ↓ 7.17% |
Total Liabilities | 43.2B | ↓ 7.94% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 62.9B | ↓ 0.33% |
Total Liabilities | 42.7B | ↓ 1.18% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 62.6B | ↓ 0.5% |
Total Liabilities | 41.5B | ↓ 2.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 349.4M | ↓ 99.45% |
Total Liabilities | 38.0M | - |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 62.3B | ↑ 17741.16% |
Total Liabilities | 14.0B | ↑ 36647.37% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.9B | ↓ 28.62% |
Investing Cash Flow | -16.1B | ↑ 34.08% |
Financing Cash Flow | 3.4B | ↓ 136.3% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.4B | ↓ 29.4% |
Investing Cash Flow | 14.4B | ↓ 189.33% |
Financing Cash Flow | -12.3B | ↓ 463.04% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 9.1B | ↑ 8.86% |
Investing Cash Flow | -7.8B | ↓ 154.45% |
Financing Cash Flow | -7.6B | ↓ 38.03% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.2B | ↓ 10.67% |
Investing Cash Flow | -14.6B | ↑ 86.96% |
Financing Cash Flow | 770.0M | ↓ 110.09% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.4B | ↑ 39.37% |
Investing Cash Flow | -3.1B | ↓ 78.58% |
Financing Cash Flow | -8.9B | ↓ 1252.86% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↓ 42.59% |
Investing Cash Flow | -1.1B | ↑ 284.89% |
Financing Cash Flow | -1.8B | ↓ 7.62% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↓ 2.07% |
Investing Cash Flow | -308.0M | ↓ 71.21% |
Financing Cash Flow | -1.0B | ↓ 44.09% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.9B | ↑ 58.88% |
Investing Cash Flow | -713.0M | ↑ 131.49% |
Financing Cash Flow | -2.1B | ↑ 111.17% |
Sell
Neutral
Buy
Gilead Sciences Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Gilead Sciences Inc. | -2.41% | -5.74% | 20.32% | 20.5% | 0.03% |
![]() Eli Lilly And Company | -0.56% | 64.54% | 79.04% | 266.39% | 420.85% |
![]() Johnson & Johnson | -3.46% | 4.7% | -3.14% | 10.19% | 15.77% |
![]() Merck & Co. Inc. | -3.51% | -0.55% | 23.39% | 28.23% | 50.52% |
![]() Abbvie Inc. | 4.12% | -3.05% | 8.17% | 77.13% | 62.87% |
![]() Pfizer Inc. | -10.14% | -18.72% | -25.42% | -9.32% | -25.35% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Gilead Sciences Inc. | 17.24 | 17.24 | 0.72 | 6.61 | 0.26 | 0.1 | 0.04 | 16.97 |
![]() Eli Lilly And Company | 76.62 | 76.62 | 2.18 | 9.77 | 0.66 | 0.1 | 0.01 | 12.3 |
![]() Johnson & Johnson | 32.72 | 32.72 | 3.79 | 9.39 | 0.17 | 0.09 | 0.03 | 28.92 |
![]() Merck & Co. Inc. | 87.48 | 87.48 | 1.36 | 3.03 | 0.08 | 0.05 | 0.03 | 15.24 |
![]() Abbvie Inc. | 31.64 | 31.64 | 1.28 | 11.06 | 0.63 | 0.09 | 0.04 | 7.29 |
![]() Pfizer Inc. | 8.74 | 8.74 | 1.17 | 3.09 | 0.23 | 0.08 | 0.05 | 17.54 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Gilead Sciences Inc. | Hold | $93.5B | 0.03% | 17.24 | 20.03% |
![]() Eli Lilly And Company | Buy | $522.2B | 420.85% | 76.62 | 22.01% |
![]() Johnson & Johnson | Hold | $389.3B | 15.77% | 32.72 | 13.35% |
![]() Merck & Co. Inc. | Buy | $270.8B | 50.52% | 87.48 | 5.34% |
![]() Abbvie Inc. | Buy | $270.8B | 62.87% | 31.64 | 15.5% |
![]() Pfizer Inc. | Hold | $185.5B | -25.35% | 8.74 | 27.55% |
BlackRock Inc
Vanguard Group Inc
Capital World Investors
State Street Corporation
Capital Research Global Investors
Dodge & Cox
In the quarter ending March,2023. Gilead Sciences Inc. has declared dividend of $0.75
Read MoreGilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Organization | Gilead Sciences Inc. |
Employees | 17000 |
CEO | Mr. Daniel P. O'Day |
Industry | Health Technology |
Schwab Us Large-cap Growth Etf
$75.01
-0.35%
Silver Trust Etf Ishares
$75.01
-0.35%
Restaurant Brands International
$75.01
-0.35%
Zillow Group, Inc. - Class C Shares
$75.01
-0.35%
Canadian National Railway Company
$75.01
-0.35%
Jpmorgan Usd Emerg Markets Bond Ishares
$75.01
-0.35%
Firstenergy Corp.
$75.01
-0.35%
Molina Healthcare, Inc.
$75.01
-0.35%
Citizens Financial Group, Inc.
$75.01
-0.35%